Skip to content
  • Contact
  • Careers
  • Spanish
SylentisSylentis
  • About Sylentis
    • Company
    • Mission and Vision
    • Team
    • Management and culture
    • Certifications and recognitions
  • Our Science
    • RNA Silencing and applications
    • Pipeline
    • Dry Eye – Tivanisiran
    • Retina – SYL1801
    • Clinical trials
    • Industrial property
  • Our Technology
    • SirFinder™
    • CDMO Services
    • Development of siRNAs
    • Capabilities
    • Services
    • Oligonucleotide manufacturing
    • Oligonucleotide analysis
    • Other services
  • Partnerships
    • Opportunities
    • Transversal Colaboration
    • Collaborative projects
    • Finalized projects
  • Talent
  • Media
    • Media contact
    • Press releases
    • Multimedia

Daily Archives: 1 de April de 2022

Destacada

Sylentis initiates a new Phase III trial in the United States to evaluate the safety of tivanisiran in patients with dry eye disease

Posted on 1 de April de 20225 de July de 2022 by sylentis
01
Apr

This Phase III study, called FYDES, will involve 26 hospitals in the United States. It will evaluate the long-term safety of tivanisiran ophthalmic solution in patients with mild to severe dry eye disease. The study has been authorized by the FDA and will be part of the New Drug Application. Madrid, April 1st, 2022. – […]

Continue reading →
Posted in Destacada

Latest news

  • Sylentis, a wholly owned subsidiary of PharmaMar, inaugurates first oligonucleotide manufacturing plant in Spain
  • Sylentis initiates a new Phase III trial in the United States to evaluate the safety of tivanisiran in patients with dry eye disease
  • Sylentis, PharmaMar Group, completes Phase I trial with SYL1801 for retinal diseases
  • Sylentis, PharmaMar Group, initiates a Phase I clinical trial with SYL1801 for retinal diseases
  • FDA authorizes Sylentis (PharmaMar Group) to initiate Phase III trial with tivanisiran for the treatment of dry eye disease

Parque Tecnológico de Madrid (PTM)
C/ Santiago Grisolía nº 2

28760 - Tres Cantos, Madrid, Spain
+34 91 804 76 67
info@sylentis.com

About Sylentis
  • Company
  • Mission and Vision
  • Team
  • Management and Culture
  • Certifications and recognitions
Careers
  • Work with us
Our Science
  • RNA silencing
  • Industrial property
  • Pipeline
  • Dry Eye – Tivanisiran
  • Retina – SYL1801
  • Clinical trials
Our Technology
  • SirFinderTM
Services
  • Oligonucleotide manufacturing
  • Oligonucleotide analysis
  • Other Services
CDMO Services
  • Development of siRNAs
  • Capabilities
Partnerships & Licensing
  • Opportunities
  • Transversal collaboration
  • Collaborative consortia
Media
  • Media contact
  • Press Releases
  • Multimedia

© 2022 Sylentis, S.A.

legal notice
privacy policy
cookies
  • About Sylentis
    • Company
    • Mission and Vision
    • Team
    • Management and culture
    • Certifications and recognitions
  • Our Science
    • RNA Silencing and applications
    • Pipeline
    • Dry Eye – Tivanisiran
    • Retina – SYL1801
    • Clinical trials
    • Industrial property
  • Our Technology
    • SirFinder™
    • CDMO Services
    • Development of siRNAs
    • Capabilities
    • Services
    • Oligonucleotide manufacturing
    • Oligonucleotide analysis
    • Other services
  • Partnerships
    • Opportunities
    • Transversal Colaboration
    • Collaborative projects
    • Finalized projects
  • Talent
  • Media
    • Media contact
    • Press releases
    • Multimedia
  • English English
    • English English
    • Español Español
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}